Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD)

NCT00862836 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

15

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of efficacy

Conditions

Ovarian Cancer

Interventions

DRUG: Vandetanib

Sponsor

Genzyme, a Sanofi Company